Skip to main content
Explore URMC

menu

Ovarian Cancer: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)

Research Question:
How effective and tolerable is treatment with the combination of cediranib and olaparib in patients with ovarian cancer?

Basic Study Information

Purpose:
The purpose of the study is to see if the combination of two drugs, cediranib and olaparib, is effective and tolerable in patients with ovarian cancer who have received at least 3 prior chemotherapy treatments, including treatment that included either carboplatin or cisplatin, and their disease came back within 6 months of the last dose of chemotherapy that included either cisplatin or carboplatin.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02889900?term=D8488C00001&rank=1
Study Reference #: IGYO-16111

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@urmc.rochester.edu

Additional Study Details

Return to Search